⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VKTX News
Viking Therapeutics, Inc
Oral Protein and Peptides Market to Hit Valuation of US$ 47.33 Billion By 2035 | Astute Analytica
globenewswire.com
VKTX
LLY
NVO
MRK
FSK
TSN
KDP
PEP
MNDO
THG
ENTX
RANI
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
prnewswire.com
VKTX
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
prnewswire.com
VKTX
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
prnewswire.com
VKTX
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
VKTX
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
prnewswire.com
NVO
ELDN
VKTX
TNDM
Next AI Superchip Sparks Investor Focus on Semiconductor Supply Chain Dynamics
accessnewswire.com
NVDA
ARM
IONQ
RKLB
VKTX
PLTR
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
prnewswire.com
VKTX
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
prnewswire.com
VKTX
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
prnewswire.com
VKTX